Kornimate/medical-research-clean huggingface dataset:
addressing psychosocial needs and hiv risk in indian msm

Conditions: HIV/STI Risk; HIV/STI Incidence

Summary: this study will develop and pilot test a combined individual and group-level behavioral hiv prevention intervention for men who have sex with men (msm) in chennai, india, addressing hiv risk within the context of broader psychosocial issues, including self-acceptance, substance use and social support.

msm in india are at increased risk for hiv in a stigmatizing environment that includes discrimination and violence. there is a need for evidence-based msm hiv prevention interventions that address hiv risk in the context of these psychosocial issues. this study consists of formative qualitative work followed by the development and testing of a pilot behavioral hiv prevention intervention for msm in chennai, india. study goals are to maximize intervention feasibility and acceptability, estimate an effect size for a power analysis, and prepare for a full-scale trial to follow. phase 1-intervention development. this phase involved the collection of formative data through msm focus groups and key informant interviews to develop a subsequent pilot behavioral intervention. phase 2-open pilot. following phase 1, the team conducted an open-phase non-randomized pilot of the intervention. enrollment involved a baseline assessment that included an interviewer-administered behavioral assessment and voluntary counseling and testing for hiv and the stis, syphilis, gonorrhea and chlamydia. eleven msm in chennai then completed 6 group sessions and 4 individual sessions over 3 months. a follow-up behavioral assessment was administered upon completion of all sessions, and 6 months after baseline participants were again administered the questionnaire and hiv/sti testing. phase 3-pilot randomized controlled trial. the study is currently in phase 3, and the data articulated in this registry is for phase 3. we are now conducting a pilot randomized controlled trial (rct) of the intervention among 6 "batches" of 8 msm in each group (n=48). comparison groups (n=48) will receive the same baseline assessment and voluntary hiv/sti counseling and testing as the intervention groups. based on phase 2 findings, the intervention groups will meet for 4 group sessions and 4 individual sessions. those assigned to receive the comparison condition will not receive these sessions. participants complete the assessments approximately 3 months after randomization, and again 3 months after that.

Eligibility criteria:
inclusion criteria: * man who has had unprotected sex with another man in past 3 months * resident of tamil nadu state, india * identifies as khothi or double-decker exclusion criteria: * does not identify as a man (i.e. hijra/ ali/transgendered) * under age 18 * unable to complete or understand informed consent procedures

Keywords: hiv psychosocial problems msm india
accessory pathway antegrade effective refractory period among wpw patients: the risk in relation to the location

Conditions: Wolff-Parkinson-White Syndrome

Summary: to correlate the antegrade effective refractory period of the accessory pathway with its anatomical location in the heart. to investigate whether the accessory pathway location can predict the high risk nature of the accessory pathway

the wolf-parkinson-white (wpw) syndrome is a clinical entity characterized by the presence of ≥1 accessory pathways between the atria and the ventricles pre-disposing patients to arrhythmias. anterograde conduction through the accessory pathway leads to preexcitation of the ventricles and a delta wave in the ecg. the prevalence of preexcitation in the general population has been estimated to be 1 to 3 in 1000 individuals. although most asymptomatic patients with pre-excitation have a good prognosis, there is also a lifetime risk of malignant arrhythmias and scd, estimated to be 0.1 % per patient year. * more worrisome is the fact that this event can be the first manifestation of the disease in up to 53 % of patients. * atrial fibrillation (af) can be a life-threatening arrhythmia in the wpw syndrome if the av ap has a short anterograde refractory period (rp), allowing too many atrial impulses to be conducted to the ventricle. * this will result in very high ventricular rates with possible deterioration into ventricular fibrillation (vf) and sudden death. * parameters proved to indicate high risk ap include ap effective refractory period \<240 ms, shortest preexcited rr interval \<250 ms * certain locations were thought to be associated with higher risk of the accessory pathway like septal localization which was significantly more frequent in patients with vf when compared with individuals with no vf but the overall number of patients is limited . . these debatable relations between ap location and its risk stratification was not extensively studied in larger scale studies....

Eligibility criteria:
1. inclusion criteria: all patients with wpw admitted to assuit university hospital and subjected to invasive eps 2. exclusion criteria: 1. heart failure 2. cardiomyopathy

Keywords: wolff-parkinson-white syndrome
sbrt combined with nimotuzumab and tislelizumab for oligoprogressive recurrent/metastatic nasopharyngeal carcinoma after failure of immunotherapy

Conditions: Nasopharyngeal Cancinoma (NPC); SBRT; Immunotherapy

Summary: this study is a single-arm, open-label, prospective, and exploratory investigation aimed at examining the short-term efficacy, specifically the objective response rate (orr), of sbrt combined with nimotuzumab followed by tislelizumab in patients with recurrent/metastatic nasopharyngeal carcinoma who have experienced oligoprogression (1-5 metastatic lesions) after immunotherapy.


Eligibility criteria:
1. inclusion criteria: 1.1. pathologically confirmed non-keratinizing nasopharyngeal carcinoma; 1.2. patients with recurrent/metastatic nasopharyngeal carcinoma who have previously received first-line treatment including anti-pd-1 immune checkpoint inhibitor therapy and failed, presenting with oligoprogression (1-5 metastatic lesions); 1.3. eligible to receive sbrt, tislelizumab, and nimotuzumab; 1.4. no history of other malignant tumors; 1.5. male or female, aged 18-75 years; 1.6. liver function: total bilirubin ≤ upper limit of normal (uln); ast and alt ≤ 2.5 × uln; alkaline phosphatase ≤ 5 × uln; 1.7. renal function: creatinine clearance ≥ 80 ml/min; 1.8. hematological tests: absolute neutrophil count (anc) ≥ 2 × 109/l, platelet count ≥ 100 × 109/l, and hemoglobin ≥ 9 g/dl; 1.9. no severe dysfunction of heart, lung, and other vital organs; 1.10. performance status (ps) score ≤ 2. 2. exclusion criteria: 2.1. disagree to sign the informed consent form; 2.2. patients who cannot comply with regular follow-ups due to psychological, social, family, or geographical reasons; 2.3. receiving other experimental treatments as part of a clinical study (during the treatment period of the clinical study); 2.4. severe, uncontrolled infections or medical conditions; 2.5. major organ dysfunction, decompensated heart, lung, kidney, or liver failure, unable to tolerate radiotherapy or immunotherapy; 2.6. factors affecting drug administration, distribution, metabolism, or excretion, such as mental abnormalities, central nervous system abnormalities, chronic diarrhea, ascites, pleural effusion, etc.; 2.7. overexposure to glucocorticoids within 2 weeks before immunotherapy; 2.8. long-term use of immunosuppressive agents after organ transplantation.
natural history and functional status study of patients with lafora disease

Conditions: Lafora Disease

Summary: a natural history and functional status study to characterize the clinical disease course in lafora disease patients using standardized, quantitative evaluations and to identify useful biomarkers and clinical outcome measures for use in future lafora treatment studies.


Eligibility criteria:
inclusion criteria: 1. documented genetic diagnosis of lafora disease based on mutations in both alleles of either the epm2a or the epm2b gene and a sibling with a known mutation in epm2a or epm2b. 2. able and willing to comply with the study protocol, including travel to study center, procedures, measurements and visits, including: 1. adequately supportive psychosocial circumstances, in the opinion of the investigator 2. caregiver/trial partner committed to facilitate patient's involvement in the study who is reliable, competent, at least 18 years of age. 3. adequate visual and auditory acuity for neuropsychological testing exclusion criteria: 1. any known genetic abnormality, including chromosomal aberrations that confound the clinical phenotype 2. subjects with: 1. complete absence of speech or 2. inability to perform any activities of daily living or 3. who are completely bedridden. 3. current participation in an interventional or therapeutic study 4. receiving an investigational drug within 90 days of the baseline visit 5. prior or current treatment with gene or stem cell therapy 6. any other diseases which may significantly interfere with the assessment of lafora disease. 7. have any other conditions, which, in the opinion of the investigator or sponsor would make the subject unsuitable for inclusion, or could interfere with the subject participating in or completing the study.

Keywords: lafora disease epm2a epm2b myoclonus epilepsy myoclonic seizures glycogen storage disease
stratified therapy on pediatric aagn

Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; ANCA-Associated Glomerulonephritis

Summary: clinical information of children with anca-associated nephritis admitted to children's hospital affiliated to chongqing medical university and partner centers from january 1, 2023 to december 31, 2023 was collected: to evaluate and compare the differences in survival, renal outcomes, and adverse reactions in children with anca-associated nephritis given different interventions according to the revised parrg risk stratification, and to evaluate the superiority of anca-associated nephritis given according to the revised parrg risk stratification. (2) to evaluate the efficacy and safety of glucocorticoid combined with rituximab and cyclophosphamide as induction regimen in high-risk group and glucocorticoid combined with rituximab as induction regimen in children with anca-associated nephritis (aagn) in low and middle risk group based on parrg risk stratification


Eligibility criteria:
inclusion criteria: * 1) newly diagnosed aagn patients with onset age of 5-17 years, complete renal biopsy and regular follow-up in the hospital; 2) all enrolled children met the following inclusion criteria: anca classification criteria: patients who meet the 2007 european medicines agency (ema) classification algorithm or the 2012 chcc definition. clinical classification includes: micropolyvasculitis (mpa), granulomatous polyvasculitis (gpa) and eosinophilic granulomatous polyvasculitis (egpa); aagn diagnostic criteria: anca vasculitis combined with any of the following: 1. hematuria: gross hematuria or microscopic hematuria: 3 times microscopic hematuria within 1 week: red blood cells \&gt in urine routine; 3 / high magnification field (hp) or \> 17 /ul (higher than normal value, can be adjusted according to the standard of the laboratory of each center); 2. proteinuria: meet any of the following: ① 3 times in 1 week urine routine protein positive; 2) 24h urinary protein quantification \&gt; 150 mg or urinary protein/creatinine (mg/mg)\&gt; 0.2; 3 urinary microalbumin higher than normal for 3 times in 1 week; 3. renal insufficiency: increased serum creatinine \&gt; 10% base or decreased creatinine clearance \&gt; 25%. exclusion criteria: - 1) patients who relied on dialysis for more than 1 month at the time of diagnosis, or the proportion of glomerular sclerosis ≥75% at the time of renal biopsy; 2) patients with severe infection (such as diffuse peritonitis, severe pneumonia, cellulitis, active epstein-barr virus infection, active cytomegalovirus infection, hepatitis b virus infection, tuberculosis infection, fungal infection, etc.) and tumor. 3) patients with other primary or secondary kidney diseases (such as iga nephropathy, membranous nephropathy, anti-glomerular basement membrane nephritis, polycystic kidney disease, renal dysplasia, urinary tract malformation, etc.); 4) parents or children refused to join the group.
anesthesia on postoperative pain after loop electrosurgical excision procedure

Conditions: Procedure, Gynecologic Surgical

Summary: the loop electrosurgical excision procedure (leep) is a modified cervical conization that is performed with an electrosurgical loop. it may be performed under local anesthesia (la) or under general anesthesia (ga), and practice patterns differ widely. in some countries, specific guidelines for the choice of anesthesia during leep are provided, whereas, in other countries, the choice of anesthesia is not specified. leep under la is more economical, obviating the need for anesthesia staff, equipment, and operating room fees. however, leep under la may be more difficult to perform, may be more difficult to learn, may lead to inferior surgical results, and may result in more pain and patient dissatisfaction. this study aimed to compare loop electrosurgical excision procedures under local anesthesia vs general anesthesia regarding patients' satisfaction, histopathologic results, and short-term morbidity


Eligibility criteria:
inclusion criteria: patients were \> 21 years old; were not pregnant the patient had one of the following indications for leep: 1. histologyproven, persistent, low-grade squamous intraepithelial lesion (lgsil); 2. a histology-proven high-grade squamous intraepithelial lesion (hgsil); 3. discrepancies between cytological reports and colposcopic impressions; 4. investigation for unsatisfactory colposcopy; 5. microinvasion or adenocarcinoma in situ on cervical punch biopsy. exclusion criteria: patients with cervical or vaginal infection; patients with an abnormal menstrual cycle; who were taking anticoagulants, patients with a coagulation defect patients with mental incapacity patients with previous hysterectomy with removal of the cervix patients with a history of cervical cancer.
rotational thromboelastometry guided blood component use in children with cirrhosis undergoing invasive procedures: a randomized controlled trial

Conditions: Cirrhosis, Liver

Summary: blood products are commonly used before invasive procedures in patients with end-stage liver diseases despite cirrhosis being a thrombophilic state. traditional coagulation tests \[namely international normalised ratio (inr) and platelets count\] are known to be unreliable in predicting bleeding risk before invasive procedures and in representing the real coagulation status of cirrhotic patients. notwithstanding they are still used to guide blood products administration before invasive procedures. rotational thromboelastometry ( rotem) has been shown to be effective in detecting signs of hypo-hypercoagulability possibly being an alternative method to guide blood products transfusion. the aim of this randomized controlled study is to evaluate the efficacy of rotem as a guide for blood products transfusion in cirrhotic children undergoing invasive procedures.

children with cirrhosis listed for invasive procedures and with deranged inr or deranged platelet count will be included in the study and will be block randomized into two groups. to prevent bleeding during the procedure, one group will receive prophylactic transfusion of either fresh frozen plasma (ffp),platelet or cryoprecipitate based on the values of inr, platelet and fibrinogen.the second group will undergo rotem based correction. following correction, the procedure will be done in both the groups. patients randomized in the rotem group will undergo repeat rotem and inr, platelet, fibrinogen testing (depending on the component transfused), post the procedure, to look at the correction achieved. similarly, patients randomized in the conventional group will undergo repeat inr, platelet, fibrinogen testing depending on the component transfused. patients will be followed for 24 hours indoors for any evidence of bleeding or transfusion reaction.

Eligibility criteria:
inclusion criteria: •children less than 18 years of age with histologic or image proven liver cirrhosis of any etiology with inr ≥ 1.5- ≤ 2.5 and/or platelet count 20,000/mm3- 50,000/mm3 and who are listed for the following invasive procedures : low risk of bleeding 1. central venous cannulation 2. haemodialysis catheter 3. ascitic or pleural tapping 4. endoscopic variceal ligation (evl) 5. endoscopic sclerotherapy (est) high risk of bleeding 6. tipps 7. endoscopic retrograde cholangiopancreatography (ercp) with sphicterotomy 8. percutaneous drain (pcd) insertion 9. biopsies other than liver biopsy for children less than 18 years with liver cirrhosis and with a platelet count between 40,000-60,000/mm3 and inr between 1.5-2.0 who are listed for 1) liver biopsy exclusion criteria: * anti platelet or anti coagulant therapy in the previous 7 days * patients with clinical evidence of disseminated intravascular coagulation (dic) and/or active bleeding * hemodialysis in the past 7 days

Keywords: rotem transfusion pre invasive procedure coagulation disorders pediatric liver disease
prevention of developmental delay and xylitol (pddax) study

Conditions: Prematurity; Neurodevelopmental Disorders

Summary: the goals of this study are to: evaluate and validate the low-cost, transportable, easily-administered malawi developmental assessment tool (mdat) for neurodevelopmental assessment of children aged 4-8 years old in malawi, as compared to the gold-standard yet more cumbersome and costly kaufman assessment battery for children-ii (kabc-ii) among (1) n=500 formerly preterm children and (2) n=500 formerly term children. additionally, we will evaluate the effects of gestational xylitol exposure compared to a lack of gestational xylitol exposure on neurodevelopmental outcomes of children aged 4-8 years old in malawi through the following four neurodevelopmental tests: (3) kabc-ii (cognitive outcomes), (4) ef touch (executive functions), (5) strengths and difficulties questionnaire (social-emotional outcomes), and (6) mdat (motor and cognitive outcomes). the researchers will leverage subjects who completed the parent prevention of prematurity and xylitol trial, which enrolled 10069 pregnant individuals in malawi and demonstrated a significant 24% reduction in incidence of preterm birth and low birthweight offspring in gravidae who chewed xylitol-containing chewing gum compared to those who did not. by ensuring that these offspring did not have higher rates of neurodevelopmental impairment, the study will promote promising multi-center international and domestic trial evaluating the impact of xylitol-containing chewing gum use and optimal dosage during pregnancy.


Eligibility criteria:
inclusion criteria: * child born during the ppax trial * enrollment age between 4-8 years old * parental or legal guardian consent obtained * willing to undergo 3 neurodevelopmental tests * willing to travel to bcmf for neurodevelopmental assessment * assent by the pediatric subject for participation in the study exclusion criteria: * parent or legal guardian cognitively unable to provide consent * child unwilling to provide assent to participate in the study

Keywords: xylitol oral health pregnancy prematurity
multimodal intervention program for patients with metabolic syndrome

Conditions: Metabolic Syndrome X

Summary: the aim of this study is to identify the psychological, emotional and lifestyle variables that can have an influence on the different components of metabolic syndrome (mets) and develop a program for change lifestyle in this patients.


Eligibility criteria:
inclusion criteria: * between 25 and 65 years age * waist circumference \>88 cm for women and \>102 cm for men * blood pressure: systolic ≥ 130 mmhg and diastolic ≥ 85 mmhg * fasting glucose level ≥ 110mg/dl * triglycerides: ≥ 150 mg/dl * hdl cholesterol ≤40 mg/dl in men and ≤50 mg/dl in women exclusion criteria: * osteoarthritis, * active inflammatory diseases, * severe psychiatric disorders and/or significant cognitive impairment assessed using the mini-mental state examination.

Keywords: metabolic syndrome mediterranean diet stress quality of life psychological factors
bicuspid aortic valve (bav) registry

Conditions: Bicuspid Aortic Valve

Summary: the purpose of this registry is to gather information on patients with bicuspid aortic valve disease.

the purpose of this registry is to gather information on patients with bicuspid aortic valve disease. the data collected in the registry will be used to assess patterns of aortic dilation, responses to medical therapy based on serial imaging and to assess for potential genetic markers of this disease

Eligibility criteria:
inclusion criteria: * any patient over the age of 18 who is able/willing to give informed consent with the diagnosis of bicuspid aortic valve disease, a family history of this disease or an ascending aortic aneurysm that is idiopathic can be included in the registry. exclusion criteria: * patients unable or unwilling to give informed consent.

Keywords: bicuspid aortic valve disease bicuspid aortic valve bav
assuring ophthalmologic follow up

Conditions: Vision Screening; Amblyopia

Summary: the goal of this study is to quantify the improvement in completed ophthalmology referrals and quantify the number of children identified and treated for amblyopia or pre amblyopic strabismus resulting from the implementation of a new referral and tracking system.

children who fail instrument vision screens at dartmouth hitchcock (d-h) community group practice (cgp) pediatric clinics will be scheduled at a community vision specialist office before departure from the pediatric clinic. if the patient does not attend the appointment (a no show) at the vision specialist office , this will be tracked and the patient will be rescheduled.

Eligibility criteria:
inclusion criteria: * all pediatrics patients without pre-existing vision problems undergoing instrument vision screening at dh pediatric cgp clinics in at ages 2,3,4,5, and 6 years of age. exclusion criteria: * all pediatric patients with pre-existing eye problems that would cause them to be excluded from the study. * all patients of parents who choose to go to an eyecare provider other than the one participating in the study (as we would be unable to make appointments or track appointments). * all patients of parents who refuse to make an appointment